MannKind reported $230.71M in Loan Capital for its fiscal quarter ending in June of 2025.


Loan Capital Change Date
Adma Biologics USD 73.4M 1.06M Jun/2025
Dynavax Technologies USD 220.75M 39.75M Jun/2025
Eli Lilly USD 34.18B 319.4M Jun/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Insmed USD 560.95M 567.39M Jun/2025
MacroGenics USD 70.26M 70.26M Jun/2025
MannKind USD 230.71M 379K Jun/2025
Merck USD 33.97B 484M Jun/2025
Novo Nordisk DKK 96.31B 44.86B Mar/2025
Pfizer USD 57.5B 137M Jun/2025
Sanofi 13.2B 211M Jun/2025
Xencor USD 94.74M 7.1M Jun/2025